Cargando…

Short-course radiotherapy for rectal cancer: real-world evidence in Argentina

BACKGROUND: Short-course radiotherapy (SCRT) of 25 Gy in five daily fractions is a recommended strategy in the neoadjuvant setting for resectable locally advanced rectal cancer (LARC), as well as in cases of metastatic disease for local control. There is scarce information regarding the use of SCRT...

Descripción completa

Detalles Bibliográficos
Autores principales: Tissera, Natalia S, Freile, Berenice, Waisberg, Federico, Esteso, Federico, Galli, Mariana, Loria, Fernando Sanchez, Luca, Romina, Pedraza, Ivana Inés, Enrico, Diego Hernán, Chacón, Carolina, Huertas, Eduardo, Chacón, Matías Rodrigo, O’Connor, Juan Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310334/
https://www.ncbi.nlm.nih.gov/pubmed/37396101
http://dx.doi.org/10.3332/ecancer.2023.1555
_version_ 1785066516856700928
author Tissera, Natalia S
Freile, Berenice
Waisberg, Federico
Esteso, Federico
Galli, Mariana
Loria, Fernando Sanchez
Luca, Romina
Pedraza, Ivana Inés
Enrico, Diego Hernán
Chacón, Carolina
Huertas, Eduardo
Chacón, Matías Rodrigo
O’Connor, Juan Manuel
author_facet Tissera, Natalia S
Freile, Berenice
Waisberg, Federico
Esteso, Federico
Galli, Mariana
Loria, Fernando Sanchez
Luca, Romina
Pedraza, Ivana Inés
Enrico, Diego Hernán
Chacón, Carolina
Huertas, Eduardo
Chacón, Matías Rodrigo
O’Connor, Juan Manuel
author_sort Tissera, Natalia S
collection PubMed
description BACKGROUND: Short-course radiotherapy (SCRT) of 25 Gy in five daily fractions is a recommended strategy in the neoadjuvant setting for resectable locally advanced rectal cancer (LARC), as well as in cases of metastatic disease for local control. There is scarce information regarding the use of SCRT for patients who have received nonoperative management. OBJECTIVES: To describe the characteristics of patients who received treatment with SCRT for LARC and metastatic rectal cancer, toxicity, and the approach after radiation treatment. METHODS: This is a retrospective analysis of all patients who underwent SCRT for rectal cancer at the Alexander Fleming Institute from March 2014 to June 2022. RESULTS: In total, 44 patients were treated with SCRT. The majority were male (29, 66%), with a median age of 59 years (interquartile range 46–73). Most patients had stage IV disease (26, 59.1%), followed by LARC (18, 40.9%). Most lesions were located in the middle rectum (30, 68%). The majority of LARC patients underwent SCRT followed by consolidation chemotherapy (ChT) (16/18, 89%), while most patients with metastatic disease underwent SCRT followed by consolidation ChT (14/26, 53.8%). A clinical complete response (cCR) was documented in 8/44, 18.2% of patients. Most patients with LARC and cCR were managed by a watch and wait approach (5/18, 27.7%). Local recurrence was observed in LARC cases (2/18, 11.1%). Patients who underwent SCRT following consolidation ChT were more likely to have adverse events (AEs) than those undergoing induction ChT following SCRT (11/30, 36.7% versus 3/12, 25%, p = 0.02) CONCLUSION: In a subgroup of patients diagnosed with LARC and treated with SCRT followed by ChT, surgical treatment could be omitted after they achieved a cCR. Local recurrence was similar to that reported in a previous study. SCRT is a reasonable option for local disease control in stage IV disease, yielding low toxicity rates. Therefore, decisions must be made by a multidisciplinary team. Prospective studies are necessary to reach further conclusions.
format Online
Article
Text
id pubmed-10310334
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-103103342023-06-30 Short-course radiotherapy for rectal cancer: real-world evidence in Argentina Tissera, Natalia S Freile, Berenice Waisberg, Federico Esteso, Federico Galli, Mariana Loria, Fernando Sanchez Luca, Romina Pedraza, Ivana Inés Enrico, Diego Hernán Chacón, Carolina Huertas, Eduardo Chacón, Matías Rodrigo O’Connor, Juan Manuel Ecancermedicalscience Short Communication BACKGROUND: Short-course radiotherapy (SCRT) of 25 Gy in five daily fractions is a recommended strategy in the neoadjuvant setting for resectable locally advanced rectal cancer (LARC), as well as in cases of metastatic disease for local control. There is scarce information regarding the use of SCRT for patients who have received nonoperative management. OBJECTIVES: To describe the characteristics of patients who received treatment with SCRT for LARC and metastatic rectal cancer, toxicity, and the approach after radiation treatment. METHODS: This is a retrospective analysis of all patients who underwent SCRT for rectal cancer at the Alexander Fleming Institute from March 2014 to June 2022. RESULTS: In total, 44 patients were treated with SCRT. The majority were male (29, 66%), with a median age of 59 years (interquartile range 46–73). Most patients had stage IV disease (26, 59.1%), followed by LARC (18, 40.9%). Most lesions were located in the middle rectum (30, 68%). The majority of LARC patients underwent SCRT followed by consolidation chemotherapy (ChT) (16/18, 89%), while most patients with metastatic disease underwent SCRT followed by consolidation ChT (14/26, 53.8%). A clinical complete response (cCR) was documented in 8/44, 18.2% of patients. Most patients with LARC and cCR were managed by a watch and wait approach (5/18, 27.7%). Local recurrence was observed in LARC cases (2/18, 11.1%). Patients who underwent SCRT following consolidation ChT were more likely to have adverse events (AEs) than those undergoing induction ChT following SCRT (11/30, 36.7% versus 3/12, 25%, p = 0.02) CONCLUSION: In a subgroup of patients diagnosed with LARC and treated with SCRT followed by ChT, surgical treatment could be omitted after they achieved a cCR. Local recurrence was similar to that reported in a previous study. SCRT is a reasonable option for local disease control in stage IV disease, yielding low toxicity rates. Therefore, decisions must be made by a multidisciplinary team. Prospective studies are necessary to reach further conclusions. Cancer Intelligence 2023-06-01 /pmc/articles/PMC10310334/ /pubmed/37396101 http://dx.doi.org/10.3332/ecancer.2023.1555 Text en © the authors; licensee ecancermedicalscience. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Tissera, Natalia S
Freile, Berenice
Waisberg, Federico
Esteso, Federico
Galli, Mariana
Loria, Fernando Sanchez
Luca, Romina
Pedraza, Ivana Inés
Enrico, Diego Hernán
Chacón, Carolina
Huertas, Eduardo
Chacón, Matías Rodrigo
O’Connor, Juan Manuel
Short-course radiotherapy for rectal cancer: real-world evidence in Argentina
title Short-course radiotherapy for rectal cancer: real-world evidence in Argentina
title_full Short-course radiotherapy for rectal cancer: real-world evidence in Argentina
title_fullStr Short-course radiotherapy for rectal cancer: real-world evidence in Argentina
title_full_unstemmed Short-course radiotherapy for rectal cancer: real-world evidence in Argentina
title_short Short-course radiotherapy for rectal cancer: real-world evidence in Argentina
title_sort short-course radiotherapy for rectal cancer: real-world evidence in argentina
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310334/
https://www.ncbi.nlm.nih.gov/pubmed/37396101
http://dx.doi.org/10.3332/ecancer.2023.1555
work_keys_str_mv AT tisseranatalias shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina
AT freileberenice shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina
AT waisbergfederico shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina
AT estesofederico shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina
AT gallimariana shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina
AT loriafernandosanchez shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina
AT lucaromina shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina
AT pedrazaivanaines shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina
AT enricodiegohernan shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina
AT chaconcarolina shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina
AT huertaseduardo shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina
AT chaconmatiasrodrigo shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina
AT oconnorjuanmanuel shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina